MODY Probability Calculator Is Suitable for MODY Screening in China

Jing Zhao, Yan Chen, Fuhui Ma, Hua Shu, Li Zheng, Yang Liu, Xia Li, Tao Xu, Zhiguang Zhou, Kaixin Zhou
Journal of the Endocrine Society, Volume 8, Issue 5, May 2024, bvae047
https://doi.org/10.1210/jendso/bvae047

Summary

Context

Selecting appropriate individuals for genetic testing is essential due to the optimal treatment for maturity-onset diabetes of the young (MODY). However, how to effectively screen for MODY in China remains unclear.

Objective

To validate the performance of current screening strategies in selecting patients with MODY based on a nationwide type 2 diabetes cohort.

Methods

A panel of 14 MODY genes was analyzed from 1911 type 2 diabetes patients who were ages 15 to 35 years. Variants were evaluated according to the American College of Medical Genetics and Genomics guidelines. Based on this cohort, we simulated the 2 most frequently used screening strategies, including the traditional MODY criteria and the MODY probability calculator (MPC), to assess their ability to select patients with MODY.

Results

From a total of 1911 participants, 42 participants harbored pathogenic/likely pathogenic variants. The performance of the traditional criteria was sensitivity: 19.0%, specificity: 72.9%, positive predictive value (PPV): 1.6%, and missing rate: 81.0%. The optimal cut-off for MPC was 40.7%. Based on this cut-off value, the performance was sensitivity: 54.8%, specificity: 81.0%, PPV: 6.1%, and missing rate: 45.2%. Moreover, hemoglobin A1c, insulin treatment, and family history of diabetes have poor discrimination between MODY and young-onset type 2 diabetes.

Conclusion

The MPC is better than traditional criteria in terms of both sensitivity and PPV. To ensure more MODY patients benefit from optimal treatment, we therefore suggest that routine genetic testing be performed on all type 2 diabetes patients who are between the ages of 15 and35 years and have MPC probability value over 40.7%.

You may also like...